Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 23, Issue 15, pp. 4095-4106
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 9, 2016
- Revision received December 5, 2016
- Accepted February 28, 2017
- Published first March 6, 2017.
Article Versions
- Previous version (March 6, 2017 - 10:03).
- Previous version (May 17, 2017 - 07:40).
- You are viewing the most recent version of this article.
Copyright & Usage
©2017 American Association for Cancer Research.
Author Information
- Rebecca Kristeleit1,*,
- Geoffrey I. Shapiro2,
- Howard A. Burris3,
- Amit M. Oza4,
- Patricia LoRusso5,
- Manish R. Patel6,
- Susan M. Domchek7,
- Judith Balmaña8,
- Yvette Drew9,
- Lee-may Chen10,
- Tamar Safra11,12,
- Ana Montes13,
- Heidi Giordano14,
- Lara Maloney14,
- Sandra Goble15,
- Jeff Isaacson16,
- Jim Xiao17,
- Jen Borrow18,
- Lindsey Rolfe19, and
- Ronnie Shapira-Frommer20
- 1Research Department of Oncology, UCL Cancer Institute, London, United Kingdom.
- 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 3Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, Tennessee.
- 4Department of Obstetrics and Gynecology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- 5Department of Medical Oncology, Yale University, New Haven, Connecticut.
- 6Department of Medical Oncology, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
- 7Department of Medical Oncology, Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania.
- 8Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- 9Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom.
- 10Department of Obstetrics, Gynecology, and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
- 11Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- 12Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 13Department of Medical Oncology, Guy's Hospital, London, United Kingdom.
- 14Clinical Science, Clovis Oncology, Inc., Boulder, Colorado.
- 15Biostatistics, Clovis Oncology, Inc., Boulder, Colorado.
- 16Statistics and Data Management, Clovis Oncology, Inc., Boulder, Colorado.
- 17Clinical Pharmacology and Nonclinical DMPK, Clovis Oncology, Inc., Boulder, Colorado.
- 18Clinical Development, Clovis Oncology, Inc., Boulder, Colorado.
- 19Clinical and Preclinical Development, Clovis Oncology, Inc., Boulder, Colorado.
- 20Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.
- ↵*Corresponding Author:
Rebecca Kristeleit, UCL Cancer Institute, 72 Huntley Street, London WC1E 6BT, United Kingdom. Phone: 4420-7679-0744; Fax: 4420-3447-9055; E-mail: r.kristeleit{at}ucl.ac.uk
August 2017
Volume 23, Issue 15
Volume 23, Issue 15
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Jump to section
Advertisement